Micafungin sodium (Synonyms: FK463, Mycamine) |
| رقم الكتالوجGC17507 |
Micafungin sodium is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthesis in Candida albicans. Micafungin sodium is the sodium salt form of Micafungin (Cat. No. GC32244), which is used to treat a variety of fungal infections, including candidiasis and aspergillosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 208538-73-2
Sample solution is provided at 25 µL, 10mM.
Micafungin sodium is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthesis in Candida albicans[1]. Micafungin sodium is the sodium salt form of Micafungin (Cat. No. GC32244), which is used to treat a variety of fungal infections, including candidiasis and aspergillosis[2]. Micafungin can inhibit dengue virus infection by disrupting viral binding, entry, and stability[3]. Micafungin has the ability to stimulate phagocytes and promote immune responses, thereby inhibiting microbial infection[4]. Micafungin is a promising inhibitor of ubiquitin-conjugating enzyme E2M (UBE2M) and can inhibit cancer cell growth[5].
In vitro, treatment of erythrocytes with Micafungin (10-25µg/mL) for 48h significantly increased the percentage of hemolyzed and annexin V-bound cells and significantly reduced forward scatter[6].
In vivo, Micafungin (1mg/kg) was injected intraperitoneally to treat mice with mucormycosis and significantly improved the survival rate of mice, but it did not exert a synergistic effect when used in combination with Isavuconazonium sulphate[7]. Treatment of mice with doxorubicin-induced cardiotoxicity with Micafungin (10, 20mg/kg) improved cardiac function and inhibited oxidative stress, mitochondrial dysfunction, and cell death in a dose-dependent manner[8].
References:
[1] Vehreschild J J, Cornely O A. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice[J]. Future Microbiology, 2006, 1(2): 161-170.
[2] Carver P L. Micafungin[J]. Annals of Pharmacotherapy, 2004, 38(10): 1707-1721.
[3] Chen Y C, Lu J W, Yeh C T, et al. Micafungin inhibits dengue virus infection through the disruption of virus binding, entry, and stability[J]. Pharmaceuticals, 2021, 14(4): 338.
[4] Fuchs B B, Li Y, Li D, et al. Micafungin elicits an immunomodulatory effect in Galleria mellonella and mice[J]. Mycopathologia, 2016, 181: 17-25.
[5] Mamun M A A, Liu S, Zhao L, et al. Micafungin: a promising inhibitor of UBE2M in cancer cell growth suppression[J]. European Journal of Medicinal Chemistry, 2023, 260: 115732.
[6] Peter T, Bissinger R, Signoretto E, et al. Micafungin-induced suicidal erythrocyte death[J]. Cellular Physiology and Biochemistry, 2016, 39(2): 584-595.
[7] Gebremariam T, Wiederhold N P, Alqarihi A, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis[J]. Journal of Antimicrobial Chemotherapy, 2016: dkw433.
[8] Lu L Q, Li M R, Huang L L, et al. Micafungin protects mouse heart against doxorubicin-induced oxidative injury via suppressing MALT1-dependent k48-linked ubiquitination of Nrf2[J]. Chemico-Biological Interactions, 2024, 400: 111179.
| Cell experiment [1]: | |
Cell lines | Erythrocytes |
Preparation Method | Erythrocytes were incubated for 48h in Ringer's solution without or with Micafungin (10-25µg/mL). Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding, as determined by flow cytometry. |
Reaction Conditions | 10-25µg/mL; 48h |
Applications | Micafungin significantly increased the percentage of annexin-V-binding cells. |
| Animal experiment [2]: | |
Animal models | Neutropenic mice |
Preparation Method | Neutropenic mice were intratracheally infected with 2.5×105 spores in 25mL PBS of M. circinelloides f. jenssenii or R. delemar 99-880 using a gelloading tip after sedation with isoflurane gas. Following inoculationthree mice were sacrificed and their lungs harvested for quantification the delivered fungal inoculum by quantitative culturing on potato dextrose agar+0.1% triton X-100. Treatment with Isavuconazonium sulphate (110 or 215mg/kg three times daily given orally), Micafungin (1mg/kg once daily, i.p.) or combination of Isavuconazonium sulphate+Micafungin started 16h postinfection and continued through day 4. Mice treated with a high dose of liposomal amphotericin B (LAmB) (15mg/kg once daily, i.v.) was included as a positive control. The primary and secondary endpoints were time to moribundity of mice infected and tissue fungal burden in lungs and brains (primary and secondary target organs) determined using quantitative PCR, respectively. |
Dosage form | 1mg/kg/day for 4 days; i.p. |
Applications | All monotherapy arms resulted in a comparable significant enhancement of 40%-60% survival when compared with placebo-treated mice. Although mice treated with Isavuconazole+Micafungin had significantly enhanced survival compared with placebo-treated mice, the combination therapy was not better than treatment with monotherapy. |
References: | |
| Cas No. | 208538-73-2 | SDF | |
| المرادفات | FK463, Mycamine | ||
| Canonical SMILES | CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O)C(CC(=O)N)O)C)O)O)O.[Na+] | ||
| Formula | C56H70N9NaO23S | M.Wt | 1292.26 |
| الذوبان | ≥ 64.66 mg/mL in DMSO, ≥ 17.5 mg/mL in Water with ultrasonic and warming | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7738 mL | 3.8692 mL | 7.7384 mL |
| 5 mM | 0.1548 mL | 0.7738 mL | 1.5477 mL |
| 10 mM | 0.0774 mL | 0.3869 mL | 0.7738 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *